Atlas Capital Advisors LLC Bei Gene, Ltd. Transaction History

Atlas Capital Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$121.11 - $216.05 $136,248 - $243,056	-1,125 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$146.52 - $269.56 $5,421 - $9,973	-37 Reduced 3.18%	1,125 $212 Million
Q3 2021 Oct 28, 2021	SELL	$249.6 - $403.14 $27,206 - $43,942	-109 Reduced 8.58%	1,162 $421,000
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $43,155 - $61,738	-195 Reduced 13.3%	1,271 $328,000
Q3 2020 Oct 23, 2020	SELL	$189.18 - $286.44 $13,431 - $20,337	-71 Reduced 4.62%	1,466 $419,000
Q2 2020 Jul 28, 2020	SELL	$123.9 - $195.41 $6,318 - $9,965	-51 Reduced 3.21%	1,537 $289,000
Q1 2020 May 04, 2020	BUY	$121.84 - $173.19 $18,032 - $25,632	148 Added 10.28%	1,588 $195,000
Q4 2019 Jan 28, 2020	SELL	$115.78 - $208.34 $5,325 - $9,583	-46 Reduced 3.1%	1,440 $238,000
Q3 2019 Nov 01, 2019	BUY	$120.61 - $148.29 $167,165 - $205,529	1,386 Added 1386.0%	1,486 $181,000
Q1 2019 Apr 29, 2019	BUY	$122.82 - $151.83 $12,282 - $15,183	100 New	100 $0

215

42M

106K

93.1K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Atlas Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Atlas Capital Advisors LLC with notifications on news.